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Abstract
Objective To assess the optimal timing and predictive value of early intra-treatment changes in multimodality functional and
molecular imaging (FMI) parameters as biomarkers for clinical remission in patients receiving chemoradiation for head and neck
squamous cell carcinoma (HNSCC).
Methods Thirty-five patients with stage III-IVb (AJCC 7th edition) HNSCC prospectively underwent 18F–FDG-PET/CT, and
diffusion-weighted (DW), dynamic contrast-enhanced (DCE) and susceptibility-weightedMRI at baseline, week 1 and week 2 of
chemoradiation. Patients with evidence of persistent or recurrent disease during follow-up were classed as non-responders.
Changes in FMI parameters at week 1 and week 2 were compared between responders and non-responders with the Mann–
Whitney U test. The significance threshold was set at a p value of <0.05.
Results There were 27 responders and 8 non-responders. Responders showed a greater reduction in PET-derived tumor total
lesion glycolysis (TLG40%; p = 0.007) and maximum standardized uptake value (SUVmax; p = 0.034) after week 1 than non-
responders but these differences were absent by week 2. In contrast, it was not until week 2 that MRI-derived parameters were
able to discriminate between the two groups: larger fractional increases in primary tumor apparent diffusion coefficient (ADC;
p < 0.001), volume transfer constant (Ktrans; p = 0.012) and interstitial space volume fraction (Ve; p = 0.047) were observed in
responders versus non-responders. ADC was the most powerful predictor (Δ >17%, AUC 0.937).
Conclusion Early intra-treatment changes in FDG-PET, DWand DCEMRI-derived parameters are predictive of ultimate response to
chemoradiation in HNSCC. However, the optimal timing for assessment with FDG-PET parameters (week 1) differed from MRI
parameters (week 2). This highlighted the importance of scanning time points for the design of FMI risk-stratified interventional studies.
Keywords Head and neck squamous cell carcinoma . MRI .
PET/CT . Chemoradiation . Biomarker
Introduction
Radical chemoradiation (CRT) is widely accepted as the standard
of care for organ-sparing treatment of locally advanced head and
neck squamous cell carcinoma (HNSCC). However, it is now
evident that locally advanced HNSCC represents a disease
spectrum rather than a single entity, with variable response to
standard CRT. Clinical variables such as tumor, node and
metastases (TNM) staging and smoking history are
prognostically robust but predictively deficient. Reliable predic-
tion of outcome early during CRT is, therefore, highly desirable
to avoid continuation of ineffective treatment and guide adapta-
tion of therapy based on response.
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Functional and molecular imaging (FMI) can characterize
tumor phenotypes by providing quantitative parameters with
radiobiological relevance. 18F–FDG-PET/CT and MRI both
have the benefit of being non-invasive, allowing serial mea-
surements during radiotherapy. Several correlation studies in
HNSCC have demonstrated varied, but complementary, bio-
logical information from different FMI parameters [1, 2]. To
date, most FMI biomarker studies in HNSCC have concen-
trated only on pre-treatment time points. Indeed, there remains
a paucity of prospective data to define the optimal time point
for early intra-treatment assessment in patients receiving CRT.
Here, we report the results of serial 18F–FDG-PET/CT, and
diffusion-weighted (DW), dynamic contrast-enhanced (DCE)
and susceptibility-weighted (SW) MRI following the first and
second week of CRT in patients with HNSCC. The primary
objective of this analysis is to identify the optimal timing and
predictive value of early intra-treatment changes in FMI pa-
rameters for ultimate response to CRT.
Materials and methods
Study design
Patients with previously untreated histologically proven
HNSCC (AJCC 7th edition stage III-IVb) and WHO perfor-
mance status 0–2 planned for CRT, were eligible for the study.
Forty patients were recruited at our institution between April
2014 and August 2016. This study received approvals from
the institutional review board (CCR3926) and research ethical
committee (13/LO/0067). All patients provided written
consent.
Patients were treated with 6 weeks of radiotherapy with
concomitant chemotherapy [cisplatin (100 mg/m2) or
carboplatin (AUC5) days 1 and 29]. Macroscopic and micro-
scopic disease received 65 Gy and 54 Gy in 30 fractions,
respectively, using intensity-modulated radiotherapy with a
simultaneous integrated boost technique.
Patients prospectively underwent 18F–FDG-PET/CT, DW,
SW and DCE MRI at baseline, week 1 (after the 4th or 5th
fraction) and week 2 (after the 9th or 10th fraction) during
treatment. Response was assessed at 3 months following com-
pletion of CRTwith MRI, 18F–FDG-PET/CT and clinical ex-
amination including nasendoscopy. Patients with evidence of
residual disease at 3 months were discussed in the multidisci-
plinary meeting for feasibility of salvage surgery. Patients
were followed up for a total of 2 years within this study.
PET/CT image acquisition
18F–FDG-PET/CT studies were acquired using Phillips
Gemini (London) and Siemens mCT (Sutton) PET/CT scan-
ners. Patients were fasted for 6 h before the study. The 18F–
FDG dose was determined according to EARL guidelines [3]
and was administered intravenously if the blood sugar level
was <10 mmol/L. Subsequently, patients rested for 60 min.
Patients were positioned on a flat-top couch in the radiother-
apy treatment position, using a headrest and 5-point thermo-
plastic shell. Unenhanced, low-dose CT was performed from
the vertex to carina for purposes of attenuation correction and
image fusion for anatomical localisation (approximate mAs
50/slice). FDG emission data were acquired from the vertex
to carina (3 min/bed; average 2-bed acquisition).
MRI image acquisition
All MRI scans were acquired on a 1.5-T scanner
(MAGNETOM Aera, Siemens Healthcare, Erlangen,
Germany). Patients were set up on a flat-top MRI couch in
the radiotherapy treatment position, using a headrest and 5-
point thermoplastic shell. A large flex and spine coils were
used. For all images, a 200 × 200-mm field of view (FOV), 2-
mm isotropic voxel size and 80-mm cranio-caudal coverage
was used. Anatomical T2-weighted [echo time/repetition time
(TE/TR): 82/11000ms] and T1-weighted (TE/TR: 13/794 ms)
were acquired first to aid functional MRI planning. DW-MRI
sequences [SE-EPI DWI, TE/TR: 61/13400, b values: 50, 400
and 800 s/mm2, monopolar diffusion gradients, number of
signal averages (NSA) = 5, bandwidth (BW) = 1000 Hz, ma-
trix 96] were then acquired.
T2* (R2* = 1/T2*) was measured using a 2D gradient echo
sequence with eight echo times [flip angle (FA) = 24, TE 4.76
to 38.08 ms in increments of 4.76 ms,
TR = 1990ms, BW = 400 Hz]. The DCE protocol included
a trans-axial 3D spoiled fast gradient echo sequence with
DIXON fat and water signal separation and TWIST under-
sampling [TE = 2.4 and 4.8 ms, TR = 7.2 ms, BW= 450 Hz,
TWIST A&B = 33%, CAIPIRIHNA (R = 4)]. A series of 12
proton density-weighted images (FA = 4°) was initially ac-
quired, followed by 100 T1-weighted acquisitions (FA = 24°)
obtained sequentially with 2-s temporal resolution.
Gadolinium (Gd) contrast agent was administered intrave-
nously at the start of the 11th dynamic scan as a bolus through
a peripherally placed cannula using an automatic injector
(0.2 mL/kg body mass, 2-mL/s injection rate; Dotarem,
Guerbet, France) and followed by a saline flush (20 mL at
2 mL/s). A full blood count was taken prior to each MRI scan
to determine blood hematocrit levels.
Image analysis
Both PETandMRI data were analyzed using RayStation (ver-
sion 4.9.9, RaySearch Medical Laboratories, AB Stockholm,
Sweden), a radiotherapy treatment planning system. Regions
of interest (ROIs) encompassing the primary tumor (PT) or/
and involved lymph nodes (LNs) were delineated on each
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imaging modality by a radiation oncologist (KW). These con-
tours were verified by respective consultants in nuclear med-
icine (WO) and radiology (AR). LNs included in the analysis
were either proven via cytology/histology results or deemed to
be unequivocally involved based on both anatomical and
functional imaging characteristics following consensus
among investigators.
PET images reconstructed using ordered subset expectation
maximization were used for analysis. A relative threshold of
40% of the maximum standardized uptake volume (SUVmax)
was used to generate the metabolic tumor volume (MTV40%).
The baseline value served as the threshold for MTV on sub-
sequent scans. PET parameters including SUVmax and total
lesion glycolysis (TLG40% = SUVmean x MTV40%) [4], were
recorded for all ROIs at each time point.
Anatomical contours for MRI were delineated on T2-
weighted images with reference to T1-weighted images. For
DW analysis, ROIs were defined on the T2-weighted low-b
value images (b50) with reference to the co-registered anatom-
ical contours, excluding regions of macroscopic necrosis and
cystic change. All b values were used to calculate the apparent
diffusion coefficient (ADC). Signal changes on multiple-
gradient echo images were used to produce spatial R2* para-
metric maps. Signal intensity decay measured for increasing
echo times was fitted on a voxel-by-voxel basis to a
monoexponential model using a least-squares fit method.
This was performed using in-house MatLab software
(MathWorks, Natick, MA, USA). The DCE data were ana-
lyzed using the MRIW software package developed by The
Institute of Cancer Research (ICR) [5]. The extended Kety
model [6] and a population-based arterial input function [7]
were used to derive a set of parameters, including the volume
transfer constant between blood plasma and extracellular ex-
travascular space (Ktrans), the total extracellular extravascular
space volume fraction (Ve) and the total blood plasma volume
fraction (Vp). For SW and DCE analysis, ROIs were defined
on co-registered T1 post-Gd images.
Due to the skewed distribution of parameter values, the
median was chosen as the statistical representation for each
individual ROI. The fractional changes in FMI parameters
from baseline [Δ = (x – baseline)/baseline] were calculated
for each scanning time point. The corresponding radiotherapy
planning CT and dosimetry were also imported to enable do-
simetric analysis.
Statistical analysis
The data were analyzed using SPSS statistical software
(Version 24.0; IBM Corp, Armonk, NY, USA). The fractional
changes in FMI parameters at week 1 and week 2 were com-
pared between responders and non-responders using the
Mann–Whitney U test. Categorical data were compared be-
tween the two groups using the Pearson Chi-squared test. The
significance threshold was set at p < 0.05. Receiver operator
characteristic (ROC) analysis was used to identify and deter-
mine the optimal threshold values for parameters with predic-
tive value.
Results
Clinical characteristics
Following exclusion of 5 patients who failed to undergo intra-
treatment scans, 35 patients were available for analysis. The
main reason for non-attendance was treatment-induced acute
side-effects. The average times from start of CRT to scanning
time points for week 1 and week 2 were 6.4 ± 1.0 days and
13.3 ± 1.0 days, respectively. Patient and tumor characteristics
are summarized in Table 1. All patients completed CRTwithin
42 days. One patient was switched from carboplatin to
cetuximab due to suboptimal renal function. The median
follow-up was 14 months (range 5–33).
Treatment outcome
There were 27 responders and 8 non-responders: 5 non-
responders had locoregional failure only, 2 had both
Table 1 Summary of
patient and tumor
characteristics
Number of patients 35
Age (y), median (range) 61 (34–69)
Sex (%)
Male 35 (100)
Female 0 (0)
Primary location (%)
Oropharynx 29 (83)
Hypopharynx/larynx 6 (17)
HPV status (%)
Positive 22 (63)
Negative 13 (37)
T classification (%)
1–2 20 (57)
3–4 15 (43)
N classification (%)
0–1 12 (34)
2–3 23 (66)
Concomitant chemotherapy (%)
Cisplatin 15 (43)
Carboplatin 10 (28)
Cis/carbo* 9 (26)
Cetuximab 1 (3)
*Cisp la t in on day 1 swi tched to
carboplatin on day 29
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locoregional and distant failure and 1 had distant metastases
without any detectable disease above the clavicles. Review of
the radiotherapy dosimetry in the non-responders with
locoregional persistence/recurrence revealed that all failures
were in-field, i.e. within clinical target volume receiving
65 Gy. Only one non-responder was deemed suitable for sal-
vage surgery and underwent total laryngectomy with bilateral
neck dissection. That patient remains disease-free to date.
Four non-responders had died at the time of analysis (5–
15 months post-CRT).
Responders versus non-responders
In this cohort, treatment-induced changes in anatomical tumor
volume in the first 2 weeks of CRT failed to discriminate
responders from non-responders (Supplementary Table 1).
Similar negative results were seen for clinical characteristics
such as HPV status and T and N classification (p > 0.05,
Supplementary Table 2).
Responders showed a greater reduction in tumor
TLG40% (p = 0.007) and SUVmax (p = 0.034) after week
1 of CRT than non-responders (Table 2). These differ-
ences between the two groups, however, disappeared by
week 2. When the data were separately analyzed per PT
and LNs, similar trends were observed but these failed
to reach statistical significance.
The fractional changes in functional MRI parameters dur-
ing CRT are summarized in Table 3. Responders showed a
larger fractional increase in PT ADC values at week 2 than
non-responders (33.7 ± 15.1% versus 11.0 ± 9.0%, p < 0.001).
Whilst there was a similar trend at week 1, it was not discrim-
inative between responders and non-responders. An example
of serial changes in PTADC is illustrated in Fig. 1. In addition,
significantly larger increases in PT Ktrans (p = 0.012) and Ve
(p = 0.047) at week 2 were observed in responders (Fig. 2).
Similarly, the differences in these parameters between the two
groups were absent at week 1.
Conversely, the changes in R2* early during CRTappeared
randomwith no apparent trend (Supplementary Fig. 1).Whilst
Table 2 Comparison of PET
parameters between responders
and non-responders (n = 35)
FMI parameters Responders (%) Non-responders (%) p value ROC (AUC)
Combined (PT + LNs)
TLG40% (g)
Baseline 112.4 ± 98.2 264.7 ± 361.0% 0.192 –
Δ post-wk 1 −56.3 ± 31.0 −18.0 ± 38.8 0.007* 0.825
Δ post-wk 2 −68.7 ± 20.9 −48.8 ± 33.3 0.131 –
SUVmax
Baseline 14.2 ± 5.2 16.6 ± 5.9 0.269 –
Δ post-wk 1 −27.8 ± 21.1 −8.1 ± 18.8 0.034* 0.764
Δ post-wk 2 −32.5 ± 23.0 −21.4 ± 19.8 0.158 –
Primary tumor (PT)
TLG40% (g)
Baseline 87.8 ± 80.1 233.5 ± 291.2 0.104 –
Δ post-wk 1 −41.3 ± 23.5 −18.3 ± 37.7 0.069 –
Δ post-wk 2 −60.2 ± 17.1 −48.2 ± 34.9 0.310 –
SUVmax
Baseline 14.7 ± 4.7 16.4 ± 6.1 0.498 –
Δ post-wk 1 −20.6 ± 12.7 −4.9 ± 18.5 0.050 –
Δ post-wk 2 −27.7 ± 14.7 −20.5 ± 18.0 0.224 –
Lymph nodes (LNs)
TLG40% (g)
Baseline 50.6 ± 57.8 70.9 ± 88.4 0.532 –
Δ post-wk 1 −56.5 ± 39.5 −16.6 ± 50.9 0.085 –
Δ post-wk 2 −65.6 ± 28.2 −52.9 ± 45.6 0.790 –
SUVmax
Baseline 10.9 ± 5.1 11.8 ± 5.2 0.859 –
Δ post-wk 1 −32.1 ± 24.1 −18.8 ± 16.6 0.391 –
Δ post-wk 2 −34.8 ± 28.1 −34.9 ± 12.2 0.533 –
*Statistically significant difference
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there was a trend for a larger decrease in PT Vp in
responders, this did not reach statistical significance.
No significant intra-treatment changes were detected in
LNs for all functional MRI parameters; however, the
trends were consistent for those for PTs.
ROC analysis identified changes in PT ADC at week 2 as
the most powerful predictor of response to CRTwith AUC of
0.937. An increase in PT ADC >17% at week 2 has a sensi-
tivity, specificity and accuracy of 100%, 86% and 96%, re-
spectively, in predicting response following CRT. For earlier
Table 3 Comparison of MRI
parameters between responders
and non-responders (n = 35)
FMI parameters Responders (%) Non-responders (%) p value ROC (AUC)
Primary (27 ROIs)
ADC (×10−3 mm2/s)
Baseline 1.02 ± 0.19 1.22 ± 0.14 0.009* 0.829
Δ post-wk 1 18.9 ± 25.5 5.1 ± 33.7 0.274 –
Δ post-wk 2 33.7 ± 15.1 11.0 ± 9.0 0.000* 0.937
R2*(s
−1)
Baseline 34.3 ± 10.5 31.4 ± 10.0 0.685 –
Δ post-wk 1 0.7 ± 23.6 −5.3 ± 25.6 0.555 –
Δ post-wk 2 −5.3 ± 25.6 4.0 ± 25.4 0.791 –
Ktrans (min−1)
Baseline 0.202 ± 0.040 0.194 ± 0.049 0.735 –
Δ post-wk 1 47.3 ± 41.6 28.2 ± 27.3 0.331 –
Δ post-wk 2 115.4 ± 117.2 13.9 ± 51.2 0.012* 0.813
Ve
Baseline 0.256 ± 0.055 0.318 ± 0.055 0.003* 0.864
Δ post-wk 1 6.9 ± 5.9 8.1 ± 22.9 0.836 –
Δ post-wk 2 12.9 ± 9.8 0.1 ± 16.6 0.047* 0.774
Vp (×10
−3)
Baseline 8.5 ± 7.4 2.7 ± 5.6 0.072 –
Δ post-wk 1 −0.52 ± 0.73 −0.03 ± 0.86 0.219 –
Δ post-wk 2 −0.53 ± 0.75 −0.16 ± 2.06 0.288 –
Lymph nodes (36 ROIs)
ADC (×10−3 mm2/s)
Baseline 1.059 ± 0.211 1.086 ± 0.091 0.456 –
Δ post-wk 1 13.6 ± 12.2 18.0 ± 7.4 0.239 –
Δ post-wk 2 33.4 ± 19.0 30.1 ± 4.4 0.900 –
R2*(s
−1)
Baseline 20.7 ± 4.7 21.1 ± 2.3 0.611 –
Δ post-wk 1 3.8 ± 18.4 4.5 ± 10.8 0.677 –
Δ post-wk 2 4.4 ± 23.0 7.4 ± 8.3 0.445 –
Ktrans (min−1)
Baseline 0.167 ± 0.044 0.204 ± 0.81 0.184 –
Δ post-wk 1 45.5 ± 42.5 64.6 ± 96.4 1.000 –
Δ post-wk 2 34.5 ± 59.7 −5.0 ± 31.3 0.102 –
Ve
Baseline 0.241 ± 0.079 0.339 ± 0.120 0.020* 0.783
Δ post-wk 1 6.8 ± 7.1 13.8 ± 14.7 0.244 –
Δ post-wk 2 11.9 ± 10.3 8.5 ± 4.3 0.694 –
Vp (×10
−3)
Baseline 4.5 ± 5.2 1.1 ± 2.6 0.229 –
Δ post-wk 1 −0.18 ± 0.50 −0.13 ± 0.28 0.944 –
Δ post-wk 2 −0.12 ± 0.67 −0.10 ± 0.30 0.813 –
*statistically significant difference
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assessment at week 1, total TLG40% was the parameter of
choice with a reduction of >12%, giving a sensitivity and
specificity of 93% and 83%, respectively, in predicting
treatment response. Attempts to combine the strongest predic-
tor, ADC, with other FMI parameters did not further improve
its performance.
Fig. 2 OverlayKtrans andVe maps demonstrating the differences in longitudinal changes between responder and non-responder after week 2 of CRT. The
responder showed a significantly larger increase in median Ktrans and Ve, in comparison to the non-responder
Fig. 1 Serial ADCmaps (tumor ROI displayed in jet color scale) in the first 2 weeks of CRT forA (non-responder) andB (responder). Patient B showed
a large treatment-induced increase in PTADC (+51.3% post-week 2) in contrast to patient A (+2.8% post-week 2)
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Discussion
We evaluated early intra-treatment assessment using
multimodality FMI parameters to predict response to CRT in
patients with locally advanced HNSCC. The reason for inves-
tigating the chosen study time points and not later, i.e.
>2 weeks, is to allow early identification of patients who are
likely or unlikely to respond so that the window of opportunity
to affect therapeutic outcome is not missed. Responders could
be considered for treatment de-escalation, e.g. radiotherapy
dose reduction or target volume adaptation, to reduce
treatment-related morbidity [8, 9]. In contrast, non-
responders should be considered for treatment intensification,
e.g. radiotherapy dose escalation [10], hypoxia modification
[11], novel radiosensitisers [12, 13] and/or ‘bail out’ surgery.
As shown in previous studies [14, 15], treatment-induced
changes in FMI parameters precede anatomical changes,
allowing earlier risk stratification of patients. Our data dem-
onstrated differing optimal times for early response assess-
ment during CRTwhen FDG-PET and MRI parameters were
used. Changes in tumor TLG40% and SUVmax at week 1 were
predictive of treatment outcome, but these signals, in fact,
disappeared later by week 2. This was explained by the low
tumor FDG uptake and lesser difference between the two
groups by week 2. Another possible confounding factor is
the influence of radiotherapy-induced peritumoral inflamma-
tion on FDG uptake with cumulative fractions, which may
affect ROI segmentation (Fig. 3), but this phenomenon is typ-
ically observed during the latter part of radiotherapy [2, 16].
This raises uncertainties about the reliability of FDG-PET
parameters in reflecting tumor response beyond the first week
of CRT. It is also evident that combined, rather than isolated,
analysis of PT and LN FDG-PET parameters provides a better
overall representation of the tumor response. To the best of our
knowledge, this is the first published data investigating the
predictive value of early intra-treatment changes in FDG-
PET parameters in such a setting.
In contrast to FDG-PET parameters, it was not until week 2
that treatment-induced changes in MRI parameters successfully
discriminated responders from non-responders. Our data showed
that a larger fractional increase in PT DW-derived ADC at week
2 (Δ > 17%) was highly predictive of favorable response to CRT.
Overall, our results are consistent with previous DWMRI stud-
ies which cumulatively reported that an increase of tumor ADC
(>14–24%) between week 1 and 4 of radiotherapy could predict
treatment outcome [17–20]. Kim et al. reported intra-treatment
assessment at week 1 to be predictive of response, but their scans
were performed on average 12 days after the start of CRT [19],
which would have been defined as week 2 in our study. Thus, it
is reasonable to deduce that whilst highly desirable, earlier as-
sessment with DW MRI (e.g. <7 days from start of CRT) is
premature and of limited utility in HNSCC.Moreover, our study
improves on previous studies due to its homogeneity: previous
studies used MRI of different strengths (1.5 and 3 T) within the
same study, had less standardized scanning time points (standard
deviation of >3 days) or/and included patients with early disease
(stage I-II) undergoing radiotherapy only.
We also found responders to have a larger fractional increase
in PT DCE-derived Ktrans and Ve. Similarly, these were only
evident by week 2. These observations are likely to reflect early
cell degradation in responding tumors, resulting in expansion
of interstitial space and increased vascular permeability. Unlike
DW MRI, there is limited data on the role of intra-treatment
DCE MRI to assess and predict response to CRT. This may be
related to the technical difficulties, e.g. tumor motion due to
swallowing and workload required to process DCE data. We
are aware of only two pilot studies which assessed changes in
DCE parameters during radical radiotherapy in patients with
HNSCC. Cao et al. reported an increase in PT blood volume
(BV) 2 weeks into CRT to be associated with local control [21].
Baer et al. subsequently investigated a novel method of using
parametric response maps of DCE MRI to predict survival
following CRT in 10 patients: they found patients with a large
percentage of PT gross volume that decreased in Ktrans after
2 weeksweremore likely to have significantly reduced survival
[22]. Our larger study supported their findings that intra-
treatment changes in Ktrans is a potential biomarker in
predicting treatment response.
Fig. 3 An example of a responder having a paradoxical increase in
primary tumor SUV at week 2 (highlighted by the blue arrow, cyan
contour = MTV40%) despite a marked initial decrease at week 1. This
phenomenon was observed in a few other responders, which may be
confounded by radiotherapy-induced peritumoral inflammation with
cumulative fractions
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In this study, we also investigated the role of SW-derived R2*
as a predictive biomarker in HNSCC. SWMRI is an alternative,
hypoxia-dependent, non-invasive imaging technique that exploits
the paramagnetic properties of deoxyhaemoglobin in erythrocytes
to create contrast. Our interest in SWMRI stems frompre-clinical
data [23] and a previous clinical study in cervical cancer demon-
strating the ability of baseline tumor R2* to predict response to
CRT: responders had a lower average baseline R2* than non-
responders [24]. This result was not replicated in our study and
we did not find any apparent trends for alterations in R2* during
the first 2 weeks of CRT. The only other R2* study in HNSCC
was recently published by Min et al. and they also failed to
demonstrate any clear pattern in its weekly changes throughout
radiotherapy [25]. They did not correlate R2* with treatment out-
come, but as with our observation, it was evident that R2* does
not appear to have a predictive role in HNSCC as a standalone
parameter. A possible explanation is that R2* values are strongly
dependent on tumor BV [26, 27], which is highly heterogeneous
in HNSCC. An accurate and robust measurement of tumor BV is
challenging [28, 29]. Therefore, additional work is required to
ascertain how best to interpret R2*measurements with BV before
it can be utilized as a hypoxia imaging biomarker in HNSCC.
Attempts to combine multiple identified FMI parameters
failed to yield superior predictive power over a single param-
eter (ΔADC at week 2) in this cohort. This may partly be due
to the relatively small number of non-responders in our study
(8/35, 23%). The risk of treatment failure is not truly binarised
by a single parameter threshold, and in ‘real-life’ clinical prac-
tice, intra-treatment changes in other predictive parameters
(TLG40%, K
trans and Ve) may prove useful in further determin-
ing the risk in equivocal cases. Our study has provided the
basic framework for early intra-treatment assessment with
FMI in locally advanced HNSCC, but requires further refine-
ment and validation with more patients. This work continues
and we are expanding our PET and functional MRI database
beyond the current study cohort.
There are limitations of this study. Eight patients with T1–2
tonsillar cancer did not have measurable PT following diag-
nostic tonsillectomy and it is unclear whether this would have
an impact on the result. In addition, the cranio-caudal cover-
age of our MRI protocol meant that in five patients, involved
LNs outside the FOVwere excluded. However, the largest LN
for each patient was included, which is likely to have been
representative of the dominant tumor biology. Another diffi-
culty was the requirement to exclude obviously necrotic or
cystic regions of the tumor, which was performed manually.
Conclusion
Our study highlighted the importance of intra-treatment scan-
ning time points when integrated into clinical practice due to
its impact on prediction outcome. This study provides the
framework of utilizing multimodality FMI early during CRT
and could be used to inform the design of future risk-stratified
adaptive interventional studies in HNSCC.
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